PMID: 9184703Jun 1, 1997Paper

Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus

The Annals of Pharmacotherapy
G E SonnenbergL D Stonesifer

Abstract

To investigate the metabolic effects and frequency of adverse events with 6 mg of glimepiride, a new oral sulfonylurea, given both in once- and twice-daily dosages to patients with non-insulin-dependent diabetes mellitus (NIDDM). This 15-week study involved 161 subjects with NIDDM. Subjects were randomized into two groups. For 4 weeks, group 1 received glimepiride 3 mg twice daily, and group 2 received glimepiride 6 mg once daily. After a 3-week placebo-washout period, twice- and once-daily regimens were crossed over for a second 4-week treatment period. Subjects were hospitalized at the end of each placebo or active-treatment phase. Their glucose concentrations were recorded at 20 time points over a 24-hour period, and their insulin and C-peptide concentrations were recorded at 16 time points over the same period. Parameters that were calculated included fasting, 24-hour, and postprandial concentrations of glucose, insulin, and C-peptide. One hundred six patients were randomized to receive treatment; 94 completed the entire study. Existing physiologic mechanisms of glucose control were apparently unimpaired by glimepiride treatment. Insulin concentrations increased more during the postprandial glucose peaks than when subjects ...Continue Reading

References

Jun 1, 1992·The Journal of Clinical Investigation·D W Landry, J A Oliver
Aug 1, 1995·Diabetes Research and Clinical Practice·E Draeger

❮ Previous
Next ❯

Citations

Jan 27, 2004·The Annals of Pharmacotherapy·Umesh A ShuklaKarl-Heinz Lehr
May 28, 2004·Pharmacotherapy·Mary T Korytkowski
Jun 28, 2007·International Journal of Clinical Practice. Supplement·G Derosa
May 5, 2001·Expert Opinion on Pharmacotherapy·A L McCall
Nov 2, 2006·Current Diabetes Reports·Jennifer B Green, Mark N Feinglos
Jan 9, 2010·Expert Opinion on Drug Metabolism & Toxicology·Vanessa J BriscoeStephen N Davis
Jan 16, 2020·Drug Development and Industrial Pharmacy·Basant A Abou-TalebSaleh H Khalil
Oct 30, 1998·The Annals of Pharmacotherapy·R K Campbell
Jan 30, 2004·Diabetes, Obesity & Metabolism·H de BoerL Verschoor
Feb 9, 2021·Journal of Diabetes and Metabolic Disorders·Debashish MondolMd Rafiqul Islam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.